June 24, 2025
National and international nominations are being sought for the 2026 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application. The Harrington Prize, which carries a $20,000...
Continue Reading
March 01, 2023
Newfound clarity on the longstanding “medical mystery” may lead to new line of drugs for oxygen delivery disorders, including peripheral artery disease, sickle cell disease, heart failure, and others Continue Reading
February 23, 2023
UVA Health School of Medicine scientists have discovered an unknown contributor to harmful blood vessel growth in the eye that could lead to new treatments for blinding macular degeneration and other common causes of vision loss. Continue Reading
February 14, 2023
Studies published from researchers at the biotech startup AcuraStem and the University of Southern California validated two potential drug targets in animal models of both genetic and sporadic ALS, paving the way for broad treatments. Continue Reading
February 14, 2023
Thylacine Biotherapeutics Inc. entered into a license agreement with Columbia University for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform. Continue Reading
February 10, 2023
Investigators discovered that a specific complex drives cell proliferation in different forms of blood cancers called mutated myeloproliferative neoplasms (MPNs), suggesting the complex could serve as an ideal therapeutic target for blood cancer. Continue Reading
February 08, 2023
In an international, multicenter, pivotal Phase 3 trial, a single under-the-skin injection of a biological drug given to patients within seven days of the onset of COVID-19 symptoms cut the likelihood they needed to be hospitalized in half. Continue Reading
January 27, 2023
Sol-Gel Technologies, Ltd. announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc. Continue Reading
January 24, 2023
A team led by investigators at Massachusetts General Hospital (MGH), including Marc Wein, MD, PhD, Massachusetts General Hospital, 2018 Harrington Scholar-Innovator, might lead to a new, more convenient drug for preventing and treating osteoporosis. Continue Reading
January 12, 2023
Dr. Christiane Wrann of Massachusetts General Hospital selected for research aimed at using the novel exercise hormone irisin to treat Alzheimer’s disease Continue Reading
November 22, 2022
Travis Dunckley, PhD, University of Arizona, 2016 ADDF-Harrington Scholar and team have developed a candidate drug they hope may successfully block the development or advancement of Alzheimer’s disease in Down syndrome patients. Continue Reading